Skip to main content
Uncategorized

New biotech venture capital firm in the PCB

By 21 de September de 2007November 18th, 2020No Comments
< Back to news
 21.09.2007

New biotech venture capital firm in the PCB

, which is currently in the process of registration with the Spanish Securities and Exchange Commission (CNMV) as a venture capital firm specialised in biotechnology, plans to capture EUR 65 million for investing in business projects in the field of healthcare innovations (Life Science & Healthcare), mainly in Spain.

As soon as it receives authorisation from the CNMV the firm will launch its first venture capital fund, Ysios BioFund I, which will make investments ranging between EUR 500,000 and EUR 4 million in biotech projects, emerging pharmaceuticals and medical technology. The fund is targeted both at early-stage companies and those already in the process of development or consolidation, including pharmaceutical spin-off companies.

The management team of what will be Ysios Capital Partners currently works in the Barcelona Science Park (PCB), although the firm’s headquarters will be located more centrally, in the Eixample district of Barcelona. The team is made up of professionals with a proven track record in venture capital, as well as in setting up and developing healthcare firms. Its members are Joël Jean-Mairet, co-founder and former chief executive of Glycart Biotechnology AG; Cristina Garmendia, president and chief executive of the Genetrix Group, and president of the Spanish Association of Bioenterprises (ASEBIO); Júlia Salaverria, former funds manager of Talde, and who has also acted as a high-level adviser to the European Commission, the European Central Bank and the Organisation for Economic Cooperation and Development (OECD); and a fourth partner with transactional and financial experience in the pharmaceutical and health sectors, who will join the team in October.